Meet the team at Booth #409
Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology drugs.
Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.
The clinical data compiled by GlobalData for Novoteoch also found that:
“By the end of 2021 40% of active immuno-oncology clinical trials involved at least one location in the Asia-Pacific region, with majority of trials conducted in China, followed by Australia, South Korea, Japan and Taiwan.
In the APAC region, the proportion of oncology trials doubled during 2017-2021.
In China, the growth in oncology trials was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immune-oncology, and leadership in cell therapy.”
Download the Reports Here:
IMMUNO-ONCOLOGY – ASIA PACIFIC – CLINICAL TRIAL LANDSCAPE
EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5
According to Yooni Kim, Vice President, Global Clinical Services Novotech:
“Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes.”
“Novotech’s service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasizes problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance.”
Novotech has recently been benchmarked as a top 10 CRO among the world’s leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.
Media contact
Toyna Chin
Novotech(Novotech-CRO.com) 소개
1997년에 설립된 노보텍(Novotech)은 글로벌 full-Service CRO이자 임상과학 자문 기업으로, 바이오텍 및 제약회사의 보다 체계적이고 성공적인 시장 진입을 지원합니다. 아시아 태평양, 북미, 유럽 전역에 걸쳐 30개 이상의 지사와 5,000개 이상의 임상시험기관과 파트너십을 구축한 노보텍은, 다양한 환자 집단과 주요 입상시험 대상에 대한 최적의 접근성을 제공하고 있습니다.
노보텍은 치료 및 규제 전문성, 고객 중심 서비스 모델, 현지 시장 인사이트, 첨단 분석 기술을 바탕으로, 환자 모집을 가속화하고, 임상시험 효율성을 극대화하며, 혁신적인 치료제를 보다 신속하게 시장에 도입하는 데 기여하고 있습니다. 이러한 노보텍의 역량은 업계에서도 높은 평가를 받고 있으며, Frost & Sullivan의 ‘Global Biotech CRO Award’를 19년 연속 수상하는 등 글로벌 CRO로서의 입지를 공고히 하고 있습니다.
더 자세한 정보나 임상시험 관련 상담이 필요하시면, 노보텍 공식 웹사이트를 (www.Novotech-CRO.com) 방문해 주시기 바랍니다.